UCBJY Quote, Financials, Valuation and Earnings

Galapagos NV has a net margin of -- compared to UCB SA's net margin of -84.26%. UCB SA's return on equity of 2.64% beat Galapagos NV's return on equity of 7.25%.

UCB SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Galapagos NV has an analysts' consensus of -- which suggests that it could grow by 15.45%. Given that Galapagos NV has higher upside potential than UCB SA, analysts believe Galapagos NV is more attractive than UCB SA.

UCB SA has a beta of 0.733, which suggesting that the stock is 26.695% less volatile than S&P 500. In comparison Galapagos NV has a beta of 0.229, suggesting its less volatile than the S&P 500 by 77.056%.

UCB SA has a quarterly dividend of $0.72 per share corresponding to a yield of 0.73%. Galapagos NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UCB SA pays 73.47% of its earnings as a dividend. Galapagos NV pays out -- of its earnings as a dividend. UCB SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

UCB SA quarterly revenues are --, which are smaller than Galapagos NV quarterly revenues of $65.8M. UCB SA's net income of -- is lower than Galapagos NV's net income of -$55.5M. Notably, UCB SA's price-to-earnings ratio is 150.75x while Galapagos NV's PE ratio is 8.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UCB SA is 6.59x versus 6.35x for Galapagos NV. Usually stocks with elevated PS ratios are considered overvalued.

MDxHealth SA has a net margin of -- compared to UCB SA's net margin of -47.99%. UCB SA's return on equity of 2.64% beat MDxHealth SA's return on equity of -650.14%.

UCB SA has a consensus price target of --, signalling downside risk potential of --. On the other hand MDxHealth SA has an analysts' consensus of -- which suggests that it could grow by 183.57%. Given that MDxHealth SA has higher upside potential than UCB SA, analysts believe MDxHealth SA is more attractive than UCB SA.

UCB SA has a beta of 0.733, which suggesting that the stock is 26.695% less volatile than S&P 500. In comparison MDxHealth SA has a beta of -390,599.621, suggesting its less volatile than the S&P 500 by 39060062.135%.

UCB SA has a quarterly dividend of $0.72 per share corresponding to a yield of 0.73%. MDxHealth SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UCB SA pays 73.47% of its earnings as a dividend. MDxHealth SA pays out -- of its earnings as a dividend. UCB SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

UCB SA quarterly revenues are --, which are smaller than MDxHealth SA quarterly revenues of $23.3M. UCB SA's net income of -- is lower than MDxHealth SA's net income of -$11.2M. Notably, UCB SA's price-to-earnings ratio is 150.75x while MDxHealth SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UCB SA is 6.59x versus 0.81x for MDxHealth SA. Usually stocks with elevated PS ratios are considered overvalued.

Mithra Pharmaceuticals SA has a net margin of -- compared to UCB SA's net margin of --. UCB SA's return on equity of 2.64% beat Mithra Pharmaceuticals SA's return on equity of --.

UCB SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Mithra Pharmaceuticals SA has an analysts' consensus of -- which suggests that it could fall by --. Given that UCB SA has higher upside potential than Mithra Pharmaceuticals SA, analysts believe UCB SA is more attractive than Mithra Pharmaceuticals SA.

UCB SA has a beta of 0.733, which suggesting that the stock is 26.695% less volatile than S&P 500. In comparison Mithra Pharmaceuticals SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

UCB SA has a quarterly dividend of $0.72 per share corresponding to a yield of 0.73%. Mithra Pharmaceuticals SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UCB SA pays 73.47% of its earnings as a dividend. Mithra Pharmaceuticals SA pays out -- of its earnings as a dividend. UCB SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

UCB SA quarterly revenues are --, which are smaller than Mithra Pharmaceuticals SA quarterly revenues of --. UCB SA's net income of -- is lower than Mithra Pharmaceuticals SA's net income of --. Notably, UCB SA's price-to-earnings ratio is 150.75x while Mithra Pharmaceuticals SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UCB SA is 6.59x versus -- for Mithra Pharmaceuticals SA. Usually stocks with elevated PS ratios are considered overvalued.

Nyxoah SA has a net margin of -- compared to UCB SA's net margin of -1347.39%. UCB SA's return on equity of 2.64% beat Nyxoah SA's return on equity of -51.1%.

UCB SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Nyxoah SA has an analysts' consensus of -- which suggests that it could grow by 96.15%. Given that Nyxoah SA has higher upside potential than UCB SA, analysts believe Nyxoah SA is more attractive than UCB SA.

UCB SA has a beta of 0.733, which suggesting that the stock is 26.695% less volatile than S&P 500. In comparison Nyxoah SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

UCB SA has a quarterly dividend of $0.72 per share corresponding to a yield of 0.73%. Nyxoah SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UCB SA pays 73.47% of its earnings as a dividend. Nyxoah SA pays out -- of its earnings as a dividend. UCB SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

UCB SA quarterly revenues are --, which are smaller than Nyxoah SA quarterly revenues of $1.4M. UCB SA's net income of -- is lower than Nyxoah SA's net income of -$18.8M. Notably, UCB SA's price-to-earnings ratio is 150.75x while Nyxoah SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UCB SA is 6.59x versus 44.41x for Nyxoah SA. Usually stocks with elevated PS ratios are considered overvalued.